Prosensa Therapeutics, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has taken on Larry Bell as its VP of regulatory affairs.
Dr Bell, who will be based in the USA, has more than 18 years’ experience in running regulatory affairs for companies including: Merck, Bristol-Myers Squibb, Aventis and Amgen.
Before setting up his own consultancy, in his most recent role he was VP and global head of regulatory affairs at GE Healthcare. At Prosensa, Dr Bell will be overseeing the company’s global regulatory activities.
He will also be active in developing appropriate regulatory strategies and effective relationships with the relevant authorities in USA, Europe and Japan.
